Advertisement

Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study

Published:December 11, 2020DOI:https://doi.org/10.1016/j.amjmed.2020.10.046

      Abstract

      Purpose

      We assessed whether sodium-glucose co-transporter type 2 (SGLT2) inhibitors are associated with a higher incidence rate of venous thromboembolism in patients with type 2 diabetes.

      Methods

      We conducted a population-based cohort study using the InGef database including patients with type 2 diabetes newly treated with noninsulin antidiabetic drugs between 2012 and 2018. Cases of venous thromboembolism identified during follow-up were matched to 40 controls on age, sex, cohort entry date, and duration of follow-up. Using a nested case-control approach, conditional logistic regression estimated incidence rate ratios (RRs) with 95% confidence intervals (CIs) of venous thromboembolism adjusted for sociodemographic and clinical variables, comparing current use of SGLT2 inhibitors with current use of dipeptidyl peptidase-4 (DPP-4) inhibitors.

      Results

      In a cohort of 219,538 patients, we identified 2152 cases of venous thromboembolism and matched them to 85,104 controls. Compared with DPP-4 inhibitors, current use of SGLT2 inhibitors was associated with a lower rate of venous thromboembolism (RR, 0.75; 95% CI, 0.59-0.94). Effect estimates were similar for dapagliflozin (RR, 0.77; 95% CI, 0.57-1.03) and empagliflozin (RR, 0.71; 95% CI, 0.52-0.98).

      Conclusions

      Compared with DPP-4 inhibitors, SGLT2 inhibitors were not associated with a higher rate of venous thromboembolism, providing reassurance regarding their thromboembolic safety.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zinman B
        • Wanner C
        • Lachin JM
        • et al.
        Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
        N Engl J Med. 2015; 373: 2117-2128
        • Neal B
        • Perkovic V
        • Mahaffey KW
        • et al.
        Canagliflozin and cardiovascular and renal events in type 2 diabetes.
        N Engl J Med. 2017; 377: 644-657
        • Wiviott SD
        • Raz I
        • Bonaca MP
        • et al.
        Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
        N Engl J Med. 2019; 380: 347-357
        • Vasilakou D
        • Karagiannis T
        • Athanasiadou E
        • et al.
        Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
        Ann Intern Med. 2013; 159: 262-274
        • Wu JH
        • Foote C
        • Blomster J
        • et al.
        Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
        Lancet Diabetes Endocrinol. 2016; 4: 411-419
        • Faillie JL
        Pharmacological aspects of the safety of gliflozins.
        Pharmacol Res. 2017; 118: 71-81
        • Braekkan SK
        • Mathiesen EB
        • Njølstad I
        • Wilsgaard T
        • Hansen J-B
        Hematocrit and risk of venous thromboembolism in a general population. The Tromsø study.
        Haematologica. 2010; 95: 270-275
        • Douros A
        • Jobski K
        • Kollhorst B
        • Schink T
        • Garbe E
        Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions.
        Br J Clin Pharmacol. 2016; 82: 839-848
        • Eischer L
        • Tscholl V
        • Heinze G
        • Traby L
        • Kyrle PA
        • Eichinger S
        Hematocrit and the risk of recurrent venous thrombosis: a prospective cohort study.
        PloS One. 2012; 7 (e38705-e38705)
        • Zhang XL
        • Zhu QQ
        • Chen YH
        • et al.
        Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis.
        J Am Heart Assoc. 2018; : 7
        • Ueda P
        • Svanstrom H
        • Melbye M
        • et al.
        Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
        BMJ. 2018; 363: k4365
        • Andersohn F
        • Walker J
        Characteristics and external validity of the German Health Risk Institute (HRI) Database.
        Pharmacoepidemiol Drug Saf. 2016; 25: 106-109
      1. 8. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2018.
        Diabetes Care. 2018; 41: S73-S85
        • Breslow NE
        • Day NE
        Statistical Methods in Cancer Research: Volume II—The Design and Analysis of Cohort Studies.
        Oxford University Press, Oxford, UK1987 (Lyon, France: International Agency for Research on Cancer, IARC Publication No. 82)
        • Suissa S
        Novel approaches to pharmacoepidemiology study design and statistical analysis.
        Pharmacoepidemiology. 2000; : 785-805
        • Cummings P
        The relative merits of risk ratios and odds ratios.
        Arch Pediatr Adolesc Med. 2009; 163: 438-445
        • Petrauskiene V
        • Falk M
        • Waernbaum I
        • Norberg M
        • Eriksson JW
        The risk of venous thromboembolism is markedly elevated in patients with diabetes.
        Diabetologia. 2005; 48: 1017-1021
        • Chang HY
        • Weiner JP
        • Richards TM
        • Bleich SN
        • Segal JB
        Validating the adapted Diabetes Complications Severity Index in claims data.
        Am J Manag Care. 2012; 18: 721-726
        • Segal JB
        • Chang HY
        • Du Y
        • Walston JD
        • Carlson MC
        • Varadhan R
        Development of a claims-based frailty indicator anchored to a well-established frailty phenotype.
        Med Care. 2017; 55: 716-722
        • Montvida O
        • Shaw J
        • Atherton JJ
        • Stringer F
        • Paul SK
        Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes.
        Diabetes Care. 2018; 41: 69-78
        • Sharma M
        • Nazareth I
        • Petersen I
        Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study.
        BMJ Open. 2016; 6e010210
        • Schneeweiss S
        • Rassen JA
        • Glynn RJ
        • Avorn J
        • Mogun H
        • Brookhart MA
        High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.
        Epidemiology. 2009; 20: 512-522
        • Douros A
        • Dell'Aniello S
        • Dehghan G
        • Boivin JF
        • Renoux C
        Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: a cohort study.
        Neurology. 2019; 93: e1010-e1020
        • Stürmer T
        • Rothman KJ
        • Avorn J
        • Glynn RJ
        Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution—a simulation study.
        Am J Epidemiol. 2010; 172: 843-854
        • McMurray JJV
        • Solomon SD
        • Inzucchi SE
        • et al.
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Wanner C
        • Inzucchi SE
        • Lachin JM
        • et al.
        Empagliflozin and progression of kidney disease in type 2 diabetes.
        N Engl J Med. 2016; 375: 323-334
        • Lip GY
        • Gibbs CR
        Does heart failure confer a hypercoagulable state? Virchow's triad revisited.
        J Am Coll Cardiol. 1999; 33: 1424-1426
        • Wattanakit K
        • Cushman M
        • Stehman-Breen C
        • Heckbert SR
        • Folsom AR
        Chronic kidney disease increases risk for venous thromboembolism.
        J Am Soc Nephrol. 2008; 19: 135-140